Your browser doesn't support javascript.
loading
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Seibel, Nita L; Steinherz, Peter G; Sather, Harland N; Nachman, James B; Delaat, Cynthia; Ettinger, Lawrence J; Freyer, David R; Mattano, Leonard A; Hastings, Caroline A; Rubin, Charles M; Bertolone, Kathy; Franklin, Janet L; Heerema, Nyla A; Mitchell, Torrey L; Pyesmany, Allan F; La, Mei K; Edens, Cheryl; Gaynon, Paul S.
Afiliación
  • Seibel NL; Hematology/Oncology, Children's National Medical Center and George Washington University School of Medicine and Public Health, 111 Michigan Avenue NW, Washington, DC 20010, USA. nseibel@cnmc.org
Blood ; 111(5): 2548-55, 2008 Mar 01.
Article en En | MEDLINE | ID: mdl-18039957
Longer and more intensive postinduction intensification (PII) improved the outcome of children and adolescents with "higher risk" acute lymphoblastic leukemia (ALL) and a slow marrow response to induction therapy. In the Children's Cancer Group study (CCG-1961), we tested longer versus more intensive PII, using a 2 x 2 factorial design for children with higher risk ALL and a rapid marrow response to induction therapy. Between November 1996 and May 2002, 2078 children and adolescents with newly diagnosed ALL (1 to 9 years old with white blood count 50 000/mm3 or more, or 10 years of age or older with any white blood count) were enrolled. After induction, 1299 patients with marrow blasts less than or equal to 25% on day 7 of induction (rapid early responders) were randomized to standard or longer duration (n = 651 + 648) and standard or increased intensity (n = 649 + 650) PII. Stronger intensity PII improved event-free survival (81% vs 72%, P < .001) and survival (89% vs 83%, P = .003) at 5 years. Differences were most apparent after 2 years from diagnosis. Longer duration PII provided no benefit. Stronger intensity but not prolonged duration PII improved outcome for patients with higher-risk ALL. This study is registered at http://clinicaltrials.gov as NCT00002812.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Blood Año: 2008 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Blood Año: 2008 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos